Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Lytix Biopharma AS ( (DE:6BG) ) has shared an update.
Lytix Biopharma AS announced the release of its third-quarter 2025 financial results, scheduled for November 18, 2025. The company will host a live webcast presentation featuring CEO Øystein Rekdal and CFO Gjest Breistein to discuss the results and provide insights, which could impact the company’s operations and industry positioning.
More about Lytix Biopharma AS
Lytix Biopharma AS, based in Oslo, Norway, is a clinical-stage biotech company specializing in developing oncolytic molecules. Their lead product, ruxotemitide, is a first-in-class oncolytic molecule aimed at maintaining durable anti-cancer immunity. The company is focused on a pipeline of molecules targeting various cancer indications and is listed on Euronext Growth Oslo.
Average Trading Volume: 65,420
Current Market Cap: NOK757.7M
Find detailed analytics on 6BG stock on TipRanks’ Stock Analysis page.